<DOC>
	<DOCNO>NCT02867397</DOCNO>
	<brief_summary>The goal current study investigate safety determine maximum tolerate dose ( MTD ) S-1 combination oxaliplatin epirubicin patient advance metastatic solid tumor .</brief_summary>
	<brief_title>Study Teysuno ( S-1 ) Combined With Epirubicin Oxaliplatin Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>1 . Had give write informed consent . 2 . Was ≥18 year age . 3 . Had advance metastatic solid tumor ( ) establish curative therapy exists . 4 . Had receive number prior therapy advance metastatic disease . 5 . Was able take medication orally . 6 . Had ECOG performance status 0 1 Cycle 1 , Day 1 7 . Had life expectancy least 3 month . 8 . Had LVEF ≥ LLN institution . 9 . Had serum troponin T CPKMB value ≤ ULN institution . 10 . Had adequate organ function define follow criterion : 1 . Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≤2.5 x ULN ; liver function abnormality due underlie liver metastasis , AST ( SGOT ) ALT ( SGPT ) ≤5 x ULN . 2 . Total serum bilirubin ≤1.5 x ULN . 3 . Absolute neutrophil count ≥1,500/mm3 ( ie , ≥1.5 x 109/L International Units [ IU ] ) ( exclude measurement obtain within 7 day administration granulocyte colonystimulating factor ( GCSF ) . 4 . Platelet count ≥100,000/mm3 ( IU : ≥100 x 109/L ) ( exclude measurement obtain within 7 day transfusion ) . 5 . Hemoglobin value ≥9.0 g/dL ( exclude measurement obtain within 7 day transfusion ) . 6 . Creatinine clearance ≥60 mL/min base calculated creatinine clearance 24hour urine collection . 11 . Was willing able comply schedule visit , treatment plan , lab test study procedure . 1 . Has treatment follow within specified time frame prior study drug administration : 1 . Major surgery within prior 4 week ( surgical incision fully heal prior study drug administration ) . 2 . Radiotherapy within prior 4 week . 3 . &gt; 25 % marrowbearing bone radiate ( PreAmendment 3 ) . 4 . Any chemotherapy within prior 3 week . 5 . Previously receive oxaliplatin S1 . 6 . Previously receive epirubicin cumulative dose &gt; 350 mg/m2 ( patient receive epirubicin cumulative dose ≤350 mg/m2 adjuvant therapy allow enroll ) . 7 . Extensive prior exposure anthracycline anthracenedione agent ( ie , prior cumulative doxorubicin exposure ≥450 mg/m2 prior mitoxantrone exposure &gt; 100 mg/m2 ) 8 . Received trastuzumab ( cardiotoxic agent ) within prior 24 week . 9 . Any investigational agent receive either concurrently within last 30 day . 10 . Current enrollment another interventional clinical study . 2 . Has serious illness medical condition ( ) include , limited , follow : 1 . Known brain metastasis leptomeningeal metastasis . 2 . Known acute systemic infection . 3 . Myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , cerebrovascular accident transient ischemic attack , pulmonary embolism , deep vein thrombosis within last 12 month . 4 . Symptomatic congestive heart failure ( New York Heart Association [ NYHA ] class III IV ( see Appendix E ) . 5 . Ongoing cardiac dysrhythmias ( ≥Grade 2 ) , atrial fibrillation ( grade ) , prolongation QTc interval ( &gt; 450 msec male ; &gt; 470 msec female ) . 6 . Hypertensive crisis severe hypertension control . 7 . Chronic nausea , vomit , diarrhea consider clinically significant opinion Investigator . 8 . ≥Grade 1 peripheral neuropathy . 9 . Recent hemoptysis , coagulopathy bleeding disorder consider Investigator clinically significant . 10 . Known nephrotic syndrome ( proteinuria &gt; 2 g/24 hour ) . 11 . Known clinically significant interstitial lung disease pulmonary fibrosis . 12 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness . 13 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment Investigator would make patient inappropriate entry study . 3 . Is receive concomitant treatment follow drug may interact S1 : 1 . Sorivudine , brivudine , uracil , eniluracil , cimetidine , folinate/folinic acid , dipyridamole ( may enhance S1 activity ) . 2 . Nitroimidazoles , include metronidazole misonidazole ( may enhance S1 activity ) 3 . Methotrexate ( may enhance S1 activity ) 4 . Clozapine ( may increase risk severity hematologic toxicity S1 ) 5 . Allopurinol ( may diminish S1 activity ) . 6 . Phenytoin ( S1 may enhance phenytoin activity ) . 7 . Flucytosine , fluorinated pyrimidine antifungal agent ( may enhance S1 activity ) . 4 . Is receive concomitant treatment follow drug may interaction epirubicin : 1 . Cimetidine ( may increase area plasma concentrationtime curve [ AUC ] epirubicin ) . 2 . Dexverapamil ( may alter pharmacokinetics epirubicin ) . 3 . Quinine ( may accelerate initial distribute epirubicin blood tissue may influence red blood cell partition epirubicin ) . 4 . Interferon alfa2b ( may cause reduction terminal elimination halflife total clearance epirubicin ) . 5 . Is pregnant lactate female . 6 . Has know hypersensitivity 5FU , epirubicin , oxaliplatin platinum compound . 7 . Patients reproductive potential refuse use adequate mean contraception ( include male patient ) . Contraceptive measure must take male female patient 6 month stop treatment S1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>